Back to companies

Xencor Inc: Overview

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward

Select Item

Xencor Inc (Xencor) is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of patients with cancer and autoimmune diseases. The company product pipeline includes XmAb819 which treats renal cell carcinoma; XmAb541 for ovarian cancer; XmAb808 targets oncology; XmAb942 for inflammatory bowel disease; Plamotamab which targets multi-drug resistant rheumatoid arthritis; and XmAb657 for autoimmune diseases. It also offers partnered programs such as JNJ-1493 for B-cell tumors; JNJ-9401 targets prostate cancer; ASP2138 treats gastric and gastroesophageal junction adenocarcinoma and pancreatic adenocarcinoma; among others. Xencor is headquartered in Pasadena, California, the US.

 Gain a 360-degree view of Xencor Inc and make more informed decisions for your business Gain a 360-degree view of Xencor Inc and make more informed decisions for your business Register your interest
Headquarters United States of America
Address Suite 200, 465 North Halstead Street, Pasadena, California, 91107
Website xencor.com
Telephone 1 626 3055900
No of Employees 260
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange XNCR (NASD)
Revenue (2024) $125.6M 13.7% (2024 vs 2023)
EPS XYZ
Net Income (2024) XYZ 60.5% (2024 vs 2023)
Market Cap* $1.1B
Net Profit Margin (2024) XYZ 65.2% (2024 vs 2023)
* As of and is in US$
View Xencor Inc financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Register your interest

Xencor Inc premium industry data and analytics

80+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Xencor Inc’s relevant decision makers and contact details.

80+

Pipeline Drugs

Identify which of Xencor Inc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

70+

Catalyst Calendar

Proactively evaluate Xencor Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

50+

Clinical Trials

Determine Xencor Inc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

11+

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

9

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

1

Investigators

Review investigator profiles and find information on trial contacts across Xencor Inc, including performance indicators like number of completed trials, and linked attributes such as rehiring statistics.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Xencor Inc’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products Brands
Pipeline Xtend
XmAb819: Renal Cell Carcinoma Ultomiris
XmAb541: Ovarian Cancer Monjuvi
XYZ
XYZ
XYZ
Understand Xencor Inc portfolio and identify potential areas for collaboration Understand Xencor Inc portfolio and identify potential areas for collaboration Register your interest
Image for loader

Competitor Comparison

Key Parameters Xencor Inc Regeneron Pharmaceuticals Inc MacroGenics Inc IGM Biosciences Inc Aptevo Therapeutics Inc
Headquarters United States of America United States of America United States of America United States of America United States of America
City Pasadena Tarrytown Rockville Mountain View Seattle
State/Province California New York Maryland California Washington
No. of Employees 260 15,410 293 16 33
Entity Type Public Public Public Private Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Register your interest
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Register your interest
Executives
Name Position Board Since Age
Bassil I. Dahiyat, Ph.D. Chief Executive Officer; Director; President Executive Board 2005 55
Bart Jan Cornelissen Senior Vice President; Chief Financial Officer Senior Management 2024 48
Dane Leone Chief Strategy Officer; Executive Vice President Senior Management 2024 -
John R. Desjarlais, Ph.D. Chief Scientific Officer; Executive Vice President - Research Senior Management 2023 61
Jennifer Sandoz Senior Vice President - Human Resources Senior Management - -
Non Dignissim Eros Proin vel Convallis 2026 XY
Non Dignissim Eros Proin vel Convallis 2026 XY
Non Dignissim Eros Proin vel Convallis 2026 XY
Gain insight into Xencor Inc key executives to enhance your sales strategy Gain insight into Xencor Inc key executives to enhance your sales strategy Register your interest
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Why are you leaving?